Growth Metrics

Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)

Keros Therapeutics posted quarterly Cash from Financing Activities of -$378.6 million for Q4 2025, down 601.21% year-on-year from $75.5 million in Q4 2024, and down 270550.71% on a QoQ basis from $140000.0 in Q3 2025.

Keros Therapeutics (KROS) has 7 years of Cash from Financing Activities data on file, last reported at -$378.6 million in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 601.21% year-over-year to -$378.6 million; the trailing twelve-month figure through Dec 2025 stood at -$378.5 million (down 196.59% YoY), and the FY2025 full-year result was -$378.5 million, down 196.59% from the prior year.
  • Cash from Financing Activities for Q4 2025 stood at -$378.6 million, down from $140000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $156.8 million in Q1 2024 and bottomed at -$378.6 million in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $2.6 million (2023), against an average of $17.1 million.
  • The widest annual swing landed in 2022, when Cash from Financing Activities jumped 138708.57%; it then slumped 601.21% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $28.4 million in 2021, then jumped by 116.13% to $61.4 million in 2022, then advanced by 12.76% to $69.3 million in 2023, then advanced by 9.08% to $75.5 million in 2024, then plunged by 601.21% to -$378.6 million in 2025.
  • The last three Cash from Financing Activities figures came in at -$378.6 million (Q4 2025), $140000.0 (Q3 2025), and $17000.0 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Keros Therapeutics 403.85 Mn 116.45 Mn - -378.63 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -378.63 Mn
Dec 31, 2025 -378.63 Mn
Sep 30, 2025 140,000.00
Sep 30, 2025 140,000.00
Jun 30, 2025 17,000.00
Jun 30, 2025 17,000.00
Mar 31, 2025 4,000.00
Mar 31, 2025 4,000.00
Dec 31, 2024 75.54 Mn
Dec 31, 2024 75.54 Mn
Sep 30, 2024 155.94 Mn
Sep 30, 2024 155.94 Mn
Jun 30, 2024 3.53 Mn
Jun 30, 2024 3.53 Mn
Mar 31, 2024 156.80 Mn
Mar 31, 2024 156.80 Mn
Dec 31, 2023 69.25 Mn
Dec 31, 2023 69.25 Mn
Sep 30, 2023 284,000.00
Sep 30, 2023 284,000.00
Jun 30, 2023 1.74 Mn
Jun 30, 2023 1.74 Mn
Mar 31, 2023 107.68 Mn
Mar 31, 2023 107.68 Mn
Dec 31, 2022 61.42 Mn
Dec 31, 2022 61.42 Mn
Sep 30, 2022 48.58 Mn
Sep 30, 2022 48.58 Mn
Jun 30, 2022 10.19 Mn
Jun 30, 2022 10.19 Mn
Mar 31, 2022 118,000.00
Mar 31, 2022 118,000.00
Dec 31, 2021 28.42 Mn
Dec 31, 2021 28.42 Mn
Sep 30, 2021 35,000.00
Sep 30, 2021 35,000.00
Jun 30, 2021 57,000.00
Jun 30, 2021 57,000.00
Mar 31, 2021 42,000.00
Mar 31, 2021 42,000.00
Dec 31, 2020 140.12 Mn
Dec 31, 2020 140.12 Mn
Sep 30, 2020 9,000.00
Sep 30, 2020 9,000.00
Jun 30, 2020 100.12 Mn
Jun 30, 2020 100.12 Mn
Mar 31, 2020 55.79 Mn
Mar 31, 2020 55.79 Mn
Dec 31, 2019 4,000.00
Dec 31, 2019 4,000.00
Sep 30, 2019 6,000.00
Sep 30, 2019 6,000.00
Jun 30, 2019 4,000.00
Jun 30, 2019 4,000.00